The Gene Center at Ludwig-Maximilians-Universität München and ExpreS2ion Biotechnologies Enter a Licensing Agreement
ExpreS2ion Biotechnologies announced the signature of a research license agreement to provide the Gene Center at Ludwig-Maximilians-Universität München with access to its Drosophila Schneider-2 cell-based technology platform - ExpreS2 - for recombinant protein production. The stable, non-lytic protein expression platform, which is fully cGMP compatible, will complement the existing capabilities in protein expression at the Gene Center. The platform will be used to address expression of complex and “challenging” proteins, including antibody fragments and other proteins.
Dr. Charlotte Dyring, CEO of ExpreS2ion Biotechnologies, said: “We are excited to sign this license agreement with the Gene Center at Ludwig-Maximilians-Universität München, a center of excellence for research into genome maintenance and the regulation of gene expression at all levels. The ExpreS2 protein expression system can respond effectively to the high demands in protein quality and quantity of structural biology projects, and it enables successful production of antibodies and antibody fragments that might fail to express in alternative systems. The Gene Center has been testing the ExpreS2 system for protein production, with very satisfying results”.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
